Endo's Qualitest subsidiary closed its $225M cash acquisition of privately held specialty generics company Boca Pharmacal, expanding its niche generics franchise in controlled substances and semi-solids. FTC required divestiture of certain generic multivitamin fluoride drops to clear the deal.